Donanemab is currently in the headlines as a drug that appears to slow down memory and thinking decline in people living with early-stage Alzheimer’s disease. Here’s what we know so far about this Alzheimer’s drug. In the last year, we have heard of two new drugs, lecanemab and donanemab, which can slow down the decline in …
In the brains of people living with Alzheimer’s disease, a protein called amyloid builds up into plaques. These plaques are thought to be toxic and damage the cells of the brain. Researchers have gone on to develop drugs which can clear amyloid from the brain. These drugs are called immunotherapies. They target the amyloid plaques …
Three promising drugs for treating Alzheimer’s disease bring fresh hope Read More »
